FDA Advisory Committee Recommends Approval Of Long-Acting Rezafungin For Treatment Of Candidemia, Invasive Candidiasis In Adults

MedPage Today (1/25, Hein) reports, “An FDA advisory committee on Tuesday overwhelmingly recommended approval, with a ‘limited use’ indication, of long-acting rezafungin for the treatment of candidemia and invasive candidiasis (IC) in adults.” In a 14-1 v...